Anti-Fibrinolytic Drugs - G20

The Anti-Fibrinolytic Drugs market is expected to achieve a revenue of US$16.94bn in 2024.
Furthermore, it is projected to experience a steady annual growth rate (CAGR 2024-2029) of 4.57%, ultimately leading to a market volume of US$21.18bn by 2029.
Among the G20 countries, United States is anticipated to generate the highest revenue, with an estimated US$9,858.00m in 2024.
In the G20 country of Germany, there is a growing demand for anti-fibrinolytic drugs due to the increasing prevalence of cardiovascular diseases.

Key regions: United Kingdom, Brazil, Europe, France, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Fibrinolytic Drugs market in G20 countries is experiencing steady growth due to the increasing prevalence of bleeding disorders and surgical procedures.

Customer preferences: Patients suffering from bleeding disorders, such as hemophilia, prefer anti-fibrinolytic drugs as they help to prevent excessive bleeding. Surgeons also prefer these drugs to reduce blood loss during surgical procedures. The ease of administration and the effectiveness of these drugs are key factors driving customer preferences.

Trends in the market: In the United States, the market for anti-fibrinolytic drugs is growing due to the increasing number of surgeries and the rising prevalence of hemophilia. The market in Japan is also growing due to the aging population and the increasing number of surgeries performed. In Europe, the market is driven by the increasing number of patients with bleeding disorders and the growing demand for effective treatments.

Local special circumstances: In China, the market for anti-fibrinolytic drugs is growing due to the increasing number of surgeries and the rising prevalence of hemophilia. However, the market is highly fragmented, with many small players competing for market share. In India, the market is growing due to the increasing number of patients with bleeding disorders and the growing demand for effective treatments. However, the market is highly price-sensitive, and companies must offer affordable products to succeed.

Underlying macroeconomic factors: The increasing prevalence of bleeding disorders and surgical procedures is the main driver of the Anti-Fibrinolytic Drugs market in G20 countries. The aging population in many countries is also contributing to the growth of the market. Additionally, the increasing awareness about bleeding disorders and the availability of effective treatments are driving market growth. However, the market is highly competitive, and companies must continue to innovate and offer affordable products to succeed.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.